,address1,city,zip,country,phone,website,industry,industryDisp,sector,sectorDisp,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,shortRatio,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToEbitda,52WeekChange,SandP52WeekChange,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,uuid,messageBoardId,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,75/76 Wimpole Street,London,W1G 9RT,United Kingdom,44 20 8004 0270,https://www.akaritx.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.",15,"{'maxAge': 1, 'name': 'Ms. Rachelle Suzanne Jacques', 'age': 51, 'title': 'Pres, CEO & Director', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 1383198, 'exercisedValue': 0, 'unexercisedValue': 13590961}",1672444800,86400,4,3.52,3.67,3.55,3.67,3.52,3.67,3.55,3.67,0.0,1.399377,-1.0735294,9317,9317,31063,25060,25060,3.51,3.66,1000,1100,18453634,2.8,13.8,3.90774,5.727935,0.0,0.0,USD,5203696,0.0,2821536,5055790,7848,12192,1690761600,1693440000,0.0016,0.23,5055790,0.481,7.588358,1672444800,1703980800,1672444800,-17748062,-5.69,-3.4,1:20,1692230400,-0.225,-0.7280179,0.14113986,NCM,EQUITY,AKTX,AKTX,Akari Therapeutics Plc,"Akari Therapeutics, Plc",1389018600,America/New_York,EDT,7ad3d9ad-13c2-3784-92d6-18475fbe0a3b,finmb_306632341,-14400000,3.65,80.0,30.0,55.0,55.0,2.0,buy,2,13249945,2.621,-23084500,0,1.1,1.147,-1.1326799,-4.83248,-6044853,-21504522,0.0,0.0,0.0,USD,
1,75/76 Wimpole Street,London,W1G 9RT,United Kingdom,44 20 8004 0270,https://www.akaritx.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.",15,"{'maxAge': 1, 'name': 'Ms. Wendy F. DiCicco CPA, CPA', 'age': 55, 'title': 'Interim Chief Financial Officer', 'yearBorn': 1967, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,3.52,3.67,3.55,3.67,3.52,3.67,3.55,3.67,0.0,1.399377,-1.0735294,9317,9317,31063,25060,25060,3.51,3.66,1000,1100,18453634,2.8,13.8,3.90774,5.727935,0.0,0.0,USD,5203696,0.0,2821536,5055790,7848,12192,1690761600,1693440000,0.0016,0.23,5055790,0.481,7.588358,1672444800,1703980800,1672444800,-17748062,-5.69,-3.4,1:20,1692230400,-0.225,-0.7280179,0.14113986,NCM,EQUITY,AKTX,AKTX,Akari Therapeutics Plc,"Akari Therapeutics, Plc",1389018600,America/New_York,EDT,7ad3d9ad-13c2-3784-92d6-18475fbe0a3b,finmb_306632341,-14400000,3.65,80.0,30.0,55.0,55.0,2.0,buy,2,13249945,2.621,-23084500,0,1.1,1.147,-1.1326799,-4.83248,-6044853,-21504522,0.0,0.0,0.0,USD,
2,75/76 Wimpole Street,London,W1G 9RT,United Kingdom,44 20 8004 0270,https://www.akaritx.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.",15,"{'maxAge': 1, 'name': 'Ms. Melissa  Bradford-Klug', 'age': 52, 'title': 'Chief Operating Officer', 'yearBorn': 1970, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,3.52,3.67,3.55,3.67,3.52,3.67,3.55,3.67,0.0,1.399377,-1.0735294,9317,9317,31063,25060,25060,3.51,3.66,1000,1100,18453634,2.8,13.8,3.90774,5.727935,0.0,0.0,USD,5203696,0.0,2821536,5055790,7848,12192,1690761600,1693440000,0.0016,0.23,5055790,0.481,7.588358,1672444800,1703980800,1672444800,-17748062,-5.69,-3.4,1:20,1692230400,-0.225,-0.7280179,0.14113986,NCM,EQUITY,AKTX,AKTX,Akari Therapeutics Plc,"Akari Therapeutics, Plc",1389018600,America/New_York,EDT,7ad3d9ad-13c2-3784-92d6-18475fbe0a3b,finmb_306632341,-14400000,3.65,80.0,30.0,55.0,55.0,2.0,buy,2,13249945,2.621,-23084500,0,1.1,1.147,-1.1326799,-4.83248,-6044853,-21504522,0.0,0.0,0.0,USD,
3,75/76 Wimpole Street,London,W1G 9RT,United Kingdom,44 20 8004 0270,https://www.akaritx.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.",15,"{'maxAge': 1, 'name': 'Dr. Miles  Nunn', 'age': 53, 'title': 'Chief Scientific Officer', 'yearBorn': 1969, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,3.52,3.67,3.55,3.67,3.52,3.67,3.55,3.67,0.0,1.399377,-1.0735294,9317,9317,31063,25060,25060,3.51,3.66,1000,1100,18453634,2.8,13.8,3.90774,5.727935,0.0,0.0,USD,5203696,0.0,2821536,5055790,7848,12192,1690761600,1693440000,0.0016,0.23,5055790,0.481,7.588358,1672444800,1703980800,1672444800,-17748062,-5.69,-3.4,1:20,1692230400,-0.225,-0.7280179,0.14113986,NCM,EQUITY,AKTX,AKTX,Akari Therapeutics Plc,"Akari Therapeutics, Plc",1389018600,America/New_York,EDT,7ad3d9ad-13c2-3784-92d6-18475fbe0a3b,finmb_306632341,-14400000,3.65,80.0,30.0,55.0,55.0,2.0,buy,2,13249945,2.621,-23084500,0,1.1,1.147,-1.1326799,-4.83248,-6044853,-21504522,0.0,0.0,0.0,USD,
4,75/76 Wimpole Street,London,W1G 9RT,United Kingdom,44 20 8004 0270,https://www.akaritx.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.",15,"{'maxAge': 1, 'name': 'Dr. John F. Neylan III, M.D.', 'age': 69, 'title': 'Exec. VP & Chief Medical Officer', 'yearBorn': 1953, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,3.52,3.67,3.55,3.67,3.52,3.67,3.55,3.67,0.0,1.399377,-1.0735294,9317,9317,31063,25060,25060,3.51,3.66,1000,1100,18453634,2.8,13.8,3.90774,5.727935,0.0,0.0,USD,5203696,0.0,2821536,5055790,7848,12192,1690761600,1693440000,0.0016,0.23,5055790,0.481,7.588358,1672444800,1703980800,1672444800,-17748062,-5.69,-3.4,1:20,1692230400,-0.225,-0.7280179,0.14113986,NCM,EQUITY,AKTX,AKTX,Akari Therapeutics Plc,"Akari Therapeutics, Plc",1389018600,America/New_York,EDT,7ad3d9ad-13c2-3784-92d6-18475fbe0a3b,finmb_306632341,-14400000,3.65,80.0,30.0,55.0,55.0,2.0,buy,2,13249945,2.621,-23084500,0,1.1,1.147,-1.1326799,-4.83248,-6044853,-21504522,0.0,0.0,0.0,USD,
5,75/76 Wimpole Street,London,W1G 9RT,United Kingdom,44 20 8004 0270,https://www.akaritx.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.",15,"{'maxAge': 1, 'name': 'Ms. Beth-Anne  Lang', 'title': 'Sr. VP of Regulatory Affairs', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,3.52,3.67,3.55,3.67,3.52,3.67,3.55,3.67,0.0,1.399377,-1.0735294,9317,9317,31063,25060,25060,3.51,3.66,1000,1100,18453634,2.8,13.8,3.90774,5.727935,0.0,0.0,USD,5203696,0.0,2821536,5055790,7848,12192,1690761600,1693440000,0.0016,0.23,5055790,0.481,7.588358,1672444800,1703980800,1672444800,-17748062,-5.69,-3.4,1:20,1692230400,-0.225,-0.7280179,0.14113986,NCM,EQUITY,AKTX,AKTX,Akari Therapeutics Plc,"Akari Therapeutics, Plc",1389018600,America/New_York,EDT,7ad3d9ad-13c2-3784-92d6-18475fbe0a3b,finmb_306632341,-14400000,3.65,80.0,30.0,55.0,55.0,2.0,buy,2,13249945,2.621,-23084500,0,1.1,1.147,-1.1326799,-4.83248,-6044853,-21504522,0.0,0.0,0.0,USD,
6,75/76 Wimpole Street,London,W1G 9RT,United Kingdom,44 20 8004 0270,https://www.akaritx.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.",15,"{'maxAge': 1, 'name': 'Annie  Mack', 'title': 'Financial Controller', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,3.52,3.67,3.55,3.67,3.52,3.67,3.55,3.67,0.0,1.399377,-1.0735294,9317,9317,31063,25060,25060,3.51,3.66,1000,1100,18453634,2.8,13.8,3.90774,5.727935,0.0,0.0,USD,5203696,0.0,2821536,5055790,7848,12192,1690761600,1693440000,0.0016,0.23,5055790,0.481,7.588358,1672444800,1703980800,1672444800,-17748062,-5.69,-3.4,1:20,1692230400,-0.225,-0.7280179,0.14113986,NCM,EQUITY,AKTX,AKTX,Akari Therapeutics Plc,"Akari Therapeutics, Plc",1389018600,America/New_York,EDT,7ad3d9ad-13c2-3784-92d6-18475fbe0a3b,finmb_306632341,-14400000,3.65,80.0,30.0,55.0,55.0,2.0,buy,2,13249945,2.621,-23084500,0,1.1,1.147,-1.1326799,-4.83248,-6044853,-21504522,0.0,0.0,0.0,USD,
